TBPH
HealthcareTheravance Biopharma, Inc. · Biotechnology · $840M
What is Theravance Biopharma, Inc.?
Theravance Biopharma is a biopharmaceutical company focused on respiratory and inflammatory disease medicines. It operates across the United States, Europe, and Asia, combining a commercialized product with an active clinical pipeline.
The company generates revenue primarily through YUPELRI, a once-daily nebulized treatment for chronic obstructive pulmonary disease. Beyond its commercial product, Theravance advances a pipeline of investigational medicines targeting inflammatory intestinal diseases, acute lung injury, pulmonary fibrosis, and autonomic disorders — pursuing selective, organ-targeted approaches designed to reduce systemic side effects.
Theravance Biopharma was founded in 2014 and is headquartered in George Town, KY.
- YUPELRI — approved once-daily nebulized COPD therapy
- Izencitinib — gut-selective JAK inhibitor in late-stage trials for ulcerative colitis and related conditions
- Ampreloxetine — investigational treatment for neurogenic orthostatic hypotension
- Nezulcitinib — lung-selective JAK inhibitor in development for acute lung injury
Is TBPH a Good Stock to Buy?
UQS Score rates TBPH as Good overall, reflecting a mixed but noteworthy profile for a small-cap biopharma.
The Risk pillar stands out as the clearest positive — suggesting the company's financial structure carries less downside exposure than many peers at this stage. Valuation is also rated Good, meaning the stock does not appear stretched relative to its fundamentals.
The Moat pillar is rated Weak, which is common for companies still building commercial scale. Quality and Growth are both Neutral, signaling a business in transition rather than one with established earnings momentum.
See the exact pillar breakdown and full financial metrics by signing up for a Pro account at UQS Score. Sign up free →
Past performance does not guarantee future results. UQS Score is based on fundamental data and is not a buy/sell recommendation.
Does TBPH pay dividends?
No — Theravance Biopharma, Inc. does not currently pay a dividend.
Theravance Biopharma does not currently pay a dividend. For a clinical-stage and early-commercial biopharma, this is typical — available capital is directed toward pipeline development, clinical trials, and commercialization efforts rather than shareholder distributions.
When does TBPH report earnings?
Theravance Biopharma reports earnings on a quarterly cadence, consistent with US-listed equities.
Results each quarter tend to reflect YUPELRI revenue trends alongside pipeline spending. Clinical milestones and trial readouts can meaningfully influence how the market interprets any given quarter's numbers.
For the most recent quarter's results and guidance, visit Theravance Biopharma's investor relations page directly.
TBPH Price History
-3.8% over 5Y
Monthly close, adjusted for stock splits and dividend reinvestment.
What if I invested in Theravance Biopharma, Inc.?
Based on Theravance Biopharma, Inc.'s historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.
TBPH Long-term Outlook
With Growth rated Neutral and Risk rated Strong, TBPH's near-term trajectory appears cautiously stable rather than rapidly expanding. The pipeline — particularly Izencitinib in late-stage trials — represents the primary source of potential upside, while the commercial base provides a degree of revenue grounding. The Good Valuation rating suggests the current price may already reflect some of that uncertainty.
Growth drivers
- Continued YUPELRI adoption in the COPD nebulized therapy market
- Potential late-stage clinical readouts for Izencitinib across multiple inflammatory indications
- Organ-selective drug design as a differentiated platform for pipeline expansion
Key risks
- Clinical trial failure risk across multiple investigational programs
- Limited commercial scale and narrow revenue base concentrated in one approved product
- Competitive pressure in both COPD and inflammatory disease therapeutic areas
TBPH vs Peers
Theravance Biopharma operates in a competitive small-cap biopharma landscape alongside companies with distinct therapeutic focuses.
Alto Neuroscience focuses on precision psychiatry and CNS disorders, a therapeutic area distinct from Theravance's respiratory and inflammatory disease emphasis.
LB Pharmaceuticals targets neurological conditions, differentiating itself from TBPH's organ-selective respiratory and gut-focused pipeline strategy.
MannKind is known for inhaled insulin delivery technology, sharing an inhalation-route focus with Theravance but operating primarily in metabolic disease rather than respiratory or inflammatory indications.
Frequently Asked Questions
What does Theravance Biopharma do?
Theravance Biopharma discovers, develops, and commercializes medicines focused on respiratory and inflammatory diseases. Its approved product, YUPELRI, treats COPD, while its pipeline targets conditions including ulcerative colitis, Crohn's disease, acute lung injury, and pulmonary fibrosis using organ-selective drug design.
Does TBPH pay dividends?
No, Theravance Biopharma does not currently pay a dividend. As a company still investing heavily in clinical development and commercialization, capital is retained to fund pipeline programs rather than distributed to shareholders.
When does TBPH report earnings?
Theravance Biopharma follows a standard quarterly earnings cadence for US-listed companies. For exact upcoming report dates, check the company's investor relations page, as our data source does not cover specific future earnings dates.
Is TBPH a good stock to buy?
UQS Score rates TBPH as Good overall. The Risk pillar is rated Strong and Valuation is Good, which are positives. However, the Moat pillar is Weak and both Quality and Growth are Neutral — reflecting the realities of a small-cap biopharma with one commercial product and an active pipeline. The full pillar breakdown is available to Pro members.
Is TBPH overvalued?
The UQS Valuation pillar for TBPH is rated Good, suggesting the stock is not obviously overpriced relative to its fundamentals. For a detailed valuation breakdown including the underlying metrics, the complete analysis is available to Pro members on UQS Score.
How does TBPH compare to its competitors?
Among small-cap biopharma peers, TBPH is distinguished by its organ-selective drug design approach and a single approved commercial product in YUPELRI. Competitors like MannKind focus on inhaled delivery in metabolic disease, while Alto Neuroscience and LB Pharmaceuticals operate in CNS and neurological spaces — different therapeutic bets entirely.
What is TBPH's market cap bracket?
Theravance Biopharma is classified as a small-cap company. This places it in a segment of the market that typically carries higher volatility and liquidity risk compared to large- or mega-cap peers, but may also offer greater upside potential tied to pipeline outcomes.
Who founded Theravance Biopharma?
Theravance Biopharma was established in 2014 as a spin-off from Theravance, Inc. Founding and leadership details are widely available through the company's public filings and investor relations materials.
Is TBPH a long-term quality investment?
From a long-term quality standpoint, TBPH's Strong Risk rating and Good Valuation are encouraging signals. However, the Weak Moat and Neutral Quality ratings indicate the company has not yet built the durable competitive advantages typically associated with high-conviction long-term holdings. Pipeline success would be key to changing that picture.
What is the main competitive advantage of Theravance Biopharma?
Theravance's core differentiation lies in its organ-selective drug design philosophy — engineering medicines to act locally in the lung or gut to reduce systemic side effects. This approach underpins both its approved COPD therapy and several pipeline candidates targeting inflammatory diseases.
Unlock Full TBPH Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓View the exact UQS Score pillar breakdown across Quality, Growth, Moat, Risk, and Valuation
- ✓Access full financial metrics and trend data behind each pillar rating
- ✓Compare TBPH against sector peers using standardized scoring
- ✓Track pipeline and commercial developments through a quality-focused lens
- ✓Get the complete analyst view available exclusively to Pro members
Pro Analysis
TBPH — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| May 22, 2026 | 54.6 | 58.8 | 30.0 | 50.5 | 82.4 | 66.4 | +0.2 |
| May 7, 2026 | 54.4 | 58.8 | 30.0 | 48.4 | 82.4 | 67.6 | 0.0 |
| May 3, 2026 | 54.4 | 58.8 | 30.0 | 48.4 | 82.4 | 67.8 | -0.1 |
| Apr 26, 2026 | 54.5 | 58.8 | 30.0 | 48.4 | 82.4 | 68.5 | +0.2 |
| Apr 19, 2026 | 54.3 | 58.8 | 30.0 | 48.4 | 82.4 | 67.0 | -0.2 |
| Apr 18, 2026 | 54.5 | 58.8 | 30.0 | 48.4 | 82.4 | 68.4 | -3.7 |
| Apr 14, 2026 | 58.2 | 58.8 | 30.0 | 48.4 | 82.4 | 93.3 | -0.1 |
| Apr 12, 2026 | 58.3 | 58.8 | 30.0 | 48.4 | 82.4 | 93.8 | -0.1 |
| Apr 9, 2026 | 58.4 | 58.8 | 30.0 | 48.4 | 82.4 | 94.8 | +1.8 |
| Apr 5, 2026 | 56.6 | 58.8 | 30.0 | 48.4 | 82.4 | 82.4 | 0.0 |
TBPH — Pillar Breakdown
Quality
— 58.8/100 (25%)Theravance Biopharma, Inc. shows solid profitability with healthy returns on capital and reasonable margins.
How effectively capital is deployed to generate returns.
Profitability relative to shareholders' equity.
Ability to convert revenue into operating profit.
Bottom-line profit as a share of revenue.
Asset productivity — how much gross profit each dollar of assets generates.
Free cash flow relative to market value.
Growth
— 50.5/100 (20%)Theravance Biopharma, Inc. shows steady but unspectacular growth, typical for mature companies.
Revenue trajectory over the last twelve months.
Compound annual revenue growth rate over 3 years.
Year-over-year earnings per share growth.
Analyst consensus for future revenue growth.
Analyst consensus for future earnings growth.
Risk
— 82.4/100 (15%)Theravance Biopharma, Inc. carries minimal financial risk with conservative leverage and strong solvency.
Debt levels relative to earnings capacity.
Total debt relative to shareholder equity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 66.4/100 (15%)Theravance Biopharma, Inc. trades at a reasonable valuation with decent earnings yield and FCF multiples.
Inverse of forward P/E — higher yield means cheaper stock.
How many years of FCF the market cap represents.
Enterprise value multiple relative to sector median.
Moat
— 30/100 (25%)Theravance Biopharma, Inc. operates in a highly competitive environment with limited sustainable advantages. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for TBPH.
Score Composition
Financial Data
More Stock Analysis
How is the TBPH UQS Score Calculated?
The UQS (Unified Quality Score) for Theravance Biopharma, Inc. is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses Theravance Biopharma, Inc.'s competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether Theravance Biopharma, Inc. is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.